Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Repligen Corporation stock

Learn how to easily invest in Repligen Corporation stock.

Repligen Corporation is a medical instruments & supplies business based in the US. Repligen Corporation shares (RGEN) are listed on the NASDAQ and all prices are listed in US Dollars. Repligen Corporation employs 1,852 staff and has a trailing 12-month revenue of around $801.3 million.

How to buy Repligen Corporation stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – RGEN. It's that simple.

Best for low fees

Finder Award

SoFi Invest


  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Best for beginners

Finder Award

eToro


  • Trade stocks and ETFs for $0 and no annual fee
  • Minimum deposit of $10 required
  • FINDER EXCLUSIVE: Get $15 when you sign up and deposit $100

Promoted for easy user experience

Robinhood


  • Get free stock upon signup
  • Earn 4% interest on uninvested cash with Robinhood Gold
  • Get 1% match on contributions to a Robinhood IRA

Repligen Corporation stock price (NASDAQ: RGEN)

Use our graph to track the performance of RGEN stocks over time.

Repligen Corporation shares at a glance

Information last updated 2023-01-26.
Latest market close$185.30
52-week range$137.21 - $262.26
50-day moving average $175.22
200-day moving average $183.07
Wall St. target price$225.55
PE ratio 65.1685
Dividend yield $0 (0%)
Earnings per share (TTM) $2.79

Buy Repligen Corporation stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Finder Award
eToro
Stocks, Options, ETFs, Cryptocurrency
$0
$10
FINDER EXCLUSIVE: Get $15
when you sign up and deposit $100
Winner of Finder’s Best Broker for Beginners award. Not available in NY, NV, MN, TN, and HI.
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Public.com
Stocks, ETFs, Cryptocurrency, Alternatives
$0
$0
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
$0
$0
N/A
Winner of Finder’s Best Overall Stock Broker award.
loading

Compare up to 4 providers

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Repligen Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Repligen Corporation price performance over time

Historical closes compared with the close of $185.3 from 2023-01-31

1 week (2023-01-25) 1.91%
1 month (2022-12-30) 9.44%
3 months (2022-11-01) -0.13%
6 months (2022-08-01) -12.82%
1 year (2022-02-01) -8.67%
2 years (2021-02-01) -10.23%
3 years (2020-01-31) 84.58%
5 years (2018-02-01) 427.62%

Is Repligen Corporation stock undervalued or overvalued?

Valuing Repligen Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Repligen Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Repligen Corporation's P/E ratio

Repligen Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 65x. In other words, Repligen Corporation shares trade at around 65x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Repligen Corporation's PEG ratio

Repligen Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.59. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Repligen Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Repligen Corporation's EBITDA

Repligen Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $263.3 million.

The EBITDA is a measure of a Repligen Corporation's overall financial performance and is widely used to measure a its profitability.

Repligen Corporation financials

Revenue TTM $801.3 million
Operating margin TTM 26.92%
Gross profit TTM $400.8 million
Return on assets TTM 5.73%
Return on equity TTM 9.37%
Profit margin 20.76%
Book value $33.05
Market capitalisation $10.1 billion

TTM: trailing 12 months

Repligen Corporation share dividends

We're not expecting Repligen Corporation to pay a dividend over the next 12 months.

Repligen Corporation share price volatility

Over the last 12 months, Repligen Corporation's shares have ranged in value from as little as $137.21 up to $262.26. A popular way to gauge a stock's volatility is its "beta".

RGEN.US volatility(beta: 1.08)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Repligen Corporation's is 1.0778. This would suggest that Repligen Corporation's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Repligen Corporation overview

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations.

Frequently asked questions

What percentage of Repligen Corporation is owned by insiders or institutions?
Currently 0.385% of Repligen Corporation shares are held by insiders and 93.39% by institutions.
How many people work for Repligen Corporation?
Latest data suggests 1,852 work at Repligen Corporation.
When does the fiscal year end for Repligen Corporation?
Repligen Corporation's fiscal year ends in December.
Where is Repligen Corporation based?
Repligen Corporation's address is: Building 1, Waltham, MA, United States, 02453
What is Repligen Corporation's ISIN number?
Repligen Corporation's international securities identification number is: US7599161095
What is Repligen Corporation's CUSIP number?
Repligen Corporation's Committee on Uniform Securities Identification Procedures number is: 759916109

More guides on Finder

Ask an Expert

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site